甲胎蛋白、甲胎蛋白异质体与肿瘤坏死因子α检测在原发性肝癌诊断中的应用价值

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application value of α-fetoprotein(AFP),α-fetoprotein heterogenes(AFP-L3)and tumor necrosis factor-α(TNF-α)detection in the diagnosis of primary liver cancer.Methods Fifty patients with primary liver cancer who were treated in Hengyang Central Hospital from January to December 2019 were selected as the research group,and 50 healthy people who came to Hengyang Central Hospital for physical examination during the same period were selected as the control group.The two groups of personnel were tested for AFP,AFP-L3 and TNF-α.The two groups were compared and analyzed for AFP,AFP-L3 and TNF-α test results,test results of patients with different pathological stages in the study group and the diagnostic power of the combined test.Results The levels of AFP,AFP-L3 and TNF-α of the study group were higher than those of the control group,the differences were statistically significant(P＜0.05).The levels of AFP,AFP-L3 and TNF-α in patients with tumor stage of Ⅲ-Ⅳwere higher than those in patients with tumor stage of Ⅰ-Ⅱ,and the differences were statistically significant(P＜0.05).The levels of AFP,AFP-L3 and TNF-α of patients in the moderately differentiated group and the well-differentiated group were lower than those of the poorly differentiated group,and the differences were statistically significant(P＜0.05).The sensitivity of the combined detection of AFP,AFP-L3 and TNF-α indicators were higher than those of independent detection,and the differences were statistically significant(P＜0.05).Conclusion The combined detection of AFP,AFP-L3 and TNF-α in patients with primary liver cancer can reflect the severity of the patient′s condition,and the detection is highly sensitive,which is beneficial to clinical application and promotion.

Key words： Primary liver cancer &alpha -fetoprotein &alpha -fetoproteine heterogeneity Tumor necrosis factor-&alpha Diagnostic power

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Dan-xia
	ZHANG Yong-hu
	GUI Ruo-hu
	WANG Xiao-yang
	WU You-xing

Cite this article:

ZHANG Dan-xia,ZHANG Yong-hu,GUI Ruo-hu, et al. Diagnostic value of α-fetoprotein,α-fetoprotein heterogenes and tumor necrosis factor-α in the diagnosis of primary liver cancer[J]. 中国当代医药, 2021, 28(26): 223-225转229.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I26/223

[1]	韩素桂，黄彩云，郑璇，等.比较用凝集素微量离心柱法和酶联免疫吸附法检测甲胎蛋白异质体对原发性肝癌的诊断价值[J].中国临床药理学杂志，2018，34（13）：1517-1519.
[2]	胡仁智，赵世巧，申波，等.血清甲胎蛋白及其异质体和异常凝血酶原对原发性肝癌的诊断价值[J].中华肝脏病杂志，2019，27（8）：634-637.
[3]	郝锐，郑雪松，张莲莲，等.5 种血清标志物在肝癌诊断中的应用价值[J].中国地方病防治杂志，2018，33（2）：9-11.
[4]	程田，唐振林.甲胎蛋白低中浓度肝细胞癌AFP-L3 和Hsp90α 联合检测临床意义[J].中华肿瘤防治杂志，2018，25（21）：1511-1514.
[5]	杨璇，孙桂荣，席强，等.高敏甲胎蛋白异质体比率在肝细胞癌诊治中的临床应用[J].中华消化杂志，2019，39（3）：181-186.
[6]	孙智珺，夏天.CT 联合血清AFP、TSGF、GP73 水平检测对原发性肝癌诊断效能的影响[J].中国地方病防治杂志，2018，33（2）：229，231.
[7]	程田，唐振林.甲胎蛋白低中浓度肝细胞癌AFP-L3 和Hsp90α 联合检测临床意义[J].中华肿瘤防治杂志，2018，25（21）：42-45.
[8]	崔琦，董延娥，霍云龙，等.血清AFP、GP73、SF、DCP 联合检测在原发性肝癌诊断中的应用[J].中国医科大学学报，2019，48（5）：434-436.
[9]	Liu Z，Jiang Y，Yuan H，et al.The trends in incidence of primary liver cancer caused by specific etiologies：Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J].J Hepatol，2019，70（4）：674-683.
[10]	查俊豪，陆建，郭金和.异常凝血酶原联合甲胎蛋白评价原发性肝癌TACE 治疗价值[J].介入放射学杂志，2019，28（6）：591-594.
[11]	李岩，郭鹏，田月洋.黄芩汤联合序贯肝动脉化疗栓塞术对原发性肝癌患者核因子κB 及细胞缺氧诱导因子-1α的影响[J].中华中医药杂志，2019，34（8）：3870-3873.
[12]	王希君，沈容芳，王想，等.甲胎蛋白高表达和低表达肝细胞肝癌的基因表达谱差异分析[J].中华肿瘤杂志，2020，42（5）：396-402.
[13]	Drake TM，Bird TG.Editorial：simplifying screening for primary liver cancer-do the LCR1 and LCR2 tests hold the key?[J].Aliment Pharm Ther，2019，49（5）：612-613.
[14]	查颖，谭娜，曾鹏飞，等.乙肝肝硬化癌变患者血清AFPL3 及HBVDNA 的变化及其可能的临床意义[J].东南大学学报（医学版），2019，38（3）：481-485.
[15]	Tavartkiladze L，Tavartkiladze A，Sordia T，et al.Chronotherapeutic regimen with liposomal cisplatin for systemic treatment of primary liver cancer[J].J Clin Oncol，2019，37（15）：e15678.
[16]	黄彩云，王晓蕊，李世龙，等.CT 扫描联合肿瘤标志物AFP-L3，GP73 诊断原发性肝癌的价值探讨[J].现代肿瘤医学，2019，27（1）：79-82.
[17]	郭致平，殷芳.甲胎蛋白、亮氨酸氨基肽酶及α-L-岩藻糖苷酶表达水平单独和联合检测诊断原发性肝癌的应用价值[J].中国综合临床，2020，36（2）：109-113.